Analysts Set uniQure N.V. (NASDAQ:QURE) Price Target at $65.00

by · The Cerbat Gem

uniQure N.V. (NASDAQ:QURE – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seventeen brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and fourteen have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $65.00.

Several research analysts recently issued reports on QURE shares. Wall Street Zen lowered shares of uniQure from a “hold” rating to a “sell” rating in a research note on Saturday. William Blair started coverage on shares of uniQure in a research note on Wednesday, September 2nd. They set an “outperform” rating on the stock. HC Wainwright upped their price objective on shares of uniQure from $50.00 to $80.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Barclays decreased their target price on shares of uniQure from $65.00 to $60.00 and set an “overweight” rating for the company in a research note on Thursday, July 30th. Finally, Wolfe Research upgraded shares of uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 target price for the company in a report on Wednesday, July 29th.

Read Our Latest Research Report on QURE

uniQure Price Performance

Shares of NASDAQ:QURE opened at $44.50 on Tuesday. uniQure has a 52-week low of $8.73 and a 52-week high of $71.50. The firm has a market capitalization of $3.09 billion, a P/E ratio of -11.10 and a beta of 0.94. The stock has a 50 day moving average price of $44.24 and a 200-day moving average price of $30.57. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.01 and a current ratio of 10.01.

uniQure (NASDAQ:QURE – Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The firm had revenue of $5.84 million during the quarter, compared to analysts’ expectations of $5.45 million. uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.During the same period in the previous year, the company earned ($0.69) earnings per share. As a group, equities research analysts anticipate that uniQure will post -3.82 EPS for the current fiscal year.

Insider Activity at uniQure

In other news, Director Madhavan Balachandran sold 11,685 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total transaction of $526,526.10. Following the sale, the director directly owned 43,254 shares in the company, valued at $1,949,025.24. This trade represents a 21.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew C. Kapusta sold 164,429 shares of uniQure stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $44.32, for a total transaction of $7,287,493.28. Following the transaction, the chief executive officer owned 558,810 shares in the company, valued at approximately $24,766,459.20. This trade represents a 22.74% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 385,584 shares of company stock worth $16,737,722 over the last quarter. 4.65% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On uniQure

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Avoro Capital Advisors LLC boosted its stake in shares of uniQure by 38.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after acquiring an additional 1,705,556 shares during the period. State Street Corp raised its stake in uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after purchasing an additional 1,787,033 shares during the period. JPMorgan Chase & Co. lifted its holdings in uniQure by 155.3% in the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after purchasing an additional 1,785,275 shares in the last quarter. California State Teachers Retirement System boosted its stake in uniQure by 6,641.2% in the 2nd quarter. California State Teachers Retirement System now owns 2,423,263 shares of the biotechnology company’s stock worth $111,615,000 after purchasing an additional 2,387,316 shares during the period. Finally, Orbimed Advisors LLC grew its holdings in uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after buying an additional 1,398,749 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

(Get Free Report)

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.

Recommended Stories